Form 4: Amgen CEO Robert Bradway Reports Stock and Option Awards

Amgen's CEO, Robert Bradway, reports the acquisition of restricted stock units and non-qualified stock options, along with adjustments to his holdings of common stock.

Summary

• Robert Bradway, CEO of Amgen, filed a Form 4 detailing changes in his beneficial ownership of Amgen stock.
• On May 6, 2025, Bradway acquired 13,311 restricted stock units (RSUs) and 86,042 non-qualified stock options.
• The RSUs vest in four equal annual installments starting May 6, 2026, and will be paid in shares of Amgen's common stock.
• The non-qualified stock options also vest in four equal annual installments starting May 6, 2026, and expire on May 6, 2035.
• Bradway directly owns 413,499 shares of Amgen common stock, including 1,424 dividend equivalents.
• He also indirectly owns 90,000 shares through a GRAT (Grantor Retained Annuity Trust) and another 90,000 shares through a spousal GRAT.

Sentiment

Score: 7

Explanation: The sentiment is neutral to positive. The document simply reports standard equity grants to the CEO, which is a common and expected practice. It signals confidence in the CEO's continued leadership.

Positives

• The grant of RSUs and stock options aligns the CEO's interests with those of the shareholders, incentivizing long-term value creation.
• The vesting schedules for both RSUs and stock options encourage continued service and commitment from the CEO.

Future Outlook

The document does not contain specific forward-looking statements, but the equity grants suggest an expectation of continued leadership and performance from the CEO.

Industry Context

Equity grants are a common practice in the pharmaceutical industry to incentivize and retain top executives. The size and terms of the grants are generally aligned with industry benchmarks and company performance.

Comparison to Industry Standards

• Equity compensation for CEOs in large-cap pharmaceutical companies like Amgen typically includes a mix of stock options and restricted stock units.
• Vesting schedules of four years are standard to ensure long-term commitment.
• Companies like Johnson & Johnson, Pfizer, and Merck also utilize similar equity incentive plans for their executives.

Stakeholder Impact

• The equity grants align the CEO's interests with those of shareholders, potentially leading to increased shareholder value.
• Employees may view the grants as a positive sign of the company's commitment to its leadership.

Key Dates

Keywords

Amgen, Robert Bradway, Form 4, Stock Options, Restricted Stock Units, RSUs, Beneficial Ownership, Equity Incentive Plan, Dividend Equivalents, Grat, Grantor Retained Annuity Trust